AndreaBozzo/ceres-open-data-index huggingface dataset:
MD COVID-19 - Contact Tracing Contacts Reached and Interviewed

<b>NOTE: THIS LAYER HAS BEEN DEPRECATED</b> (last updated 5/31/2022). Was formerly a weekly update.

<b>Summary</b>
The cumulative total of confirmed COVID-19 case contacts that have been entered into covidLINK and have been reached for contact tracing interviews as of the date of report.

<b>Description</b>
The MD COVID-19 - Contact Tracing Contacts Reached and Interviewed data layer reflects the cumulative total of confirmed COVID-19 case contacts that have been entered into covidLINK and have been reached for contact tracing interviews as of the date of report. Individuals that responded to outreach attempts and were veriﬁed as the intended call recipient are considered successfully reached. Not responding to calls is the primary reason contacts are not successfully reached. For contacts reached, reasons for not completing an interview include scheduling conﬂict, hospitalization/incapacitation, and refusal to participate. Data are updated weekly on Wednesday during the 10 a.m. hour (data is reported through the previous Saturday).

<b>Terms of Use</b>
The Spatial Data, and the information therein, (collectively the "Data") is provided "as is" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.
Compound 528928: Benzaldehyde, 2-hydroxy, 5-butyl, oxime, TMS

Chemical compound data from PubChem database. IUPAC Name: 1-(5-butyl-2-trimethylsilyloxyphenyl)-N-trimethylsilyloxymethanimine. Molecular Formula: C17H31NO2Si2. Molecular Weight: 337.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528957: Phenol, 2-(1-methylpentyl)-4-nitro

Chemical compound data from PubChem database. IUPAC Name: 2-hexan-2-yl-4-nitrophenol. Molecular Formula: C12H17NO3. Molecular Weight: 223.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Managed Care Individual Provider Network Data: September 30, 2014

This dataset contains individual provider netowrk data.The primary purpose for the Provider Network Data System is to collect data needed to evaluate the provider networks including physicians, hospitals, labs, home health agencies, durable medical equipment providers, etc., for all types of Managed Care plans in New York State, including HIV Special Need Plans (SNP), Family Health Plus (FHP) Buy-In, Programs of All-Inclusive Care for the Elderly (PACE), and Non-PACE Managed Long-Term Care (MLTC) plans. For more information, check out:  http://www.health.ny.gov/health_care/managed_care/.
Debate: PCI or CABG for multivessel disease? Viewpoint: No clear winner in an unfair fight

The Arterial Revascularization Therapy Study (ARTS) and the Stent or Surgery (SoS) trial each randomized patients with multivessel disease to either stenting or bypass surgery. The ARTS showed no difference in mortality between the two strategies, other than in diabetic patients, who fared better with surgery. The SoS trial demonstrated increased mortality in the stent arm, a difference that was not attributable to diabetes. Both trials found that the rates of repeat revascularization were lower with surgery, although the rate with stenting was much lower than had been seen in previous trials of angioplasty. Use of antiplatelet therapy such as intravenous glycoprotein IIb/IIIa inhibitors, especially with their pronounced effects in diabetics and in those with multivessel disease, could potentially equalize the playing field or perhaps even tip the balance in favor of percutaneous intervention.
Compound 529071: 4H-Pyrrolo2,1-d-1,3,5-dithiazine, 2-butyltetrahydro-4-methyl-

Chemical compound data from PubChem database. IUPAC Name: 2-butyl-4-methyl-6,7,8,8a-tetrahydro-4H-pyrrolo[2,1-d][1,3,5]dithiazine. Molecular Formula: C11H21NS2. Molecular Weight: 231.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529162: 1-Hexanol, 6-amino, N-isopropylidene

Chemical compound data from PubChem database. IUPAC Name: 6-(propan-2-ylideneamino)hexan-1-ol. Molecular Formula: C9H19NO. Molecular Weight: 157.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E40012-T1: [Translated] PLUG PART FOR DETACHABLE PLUG-IN CONNECTIONS OF FIBER OPTIC CONDUCTORS, PROCESS FOR ITS MANUFACTURE AND DEVICE FOR CARRYING OUT THE PROCESS.

1. Method of manufacturing a connector for detachable plug-and-socket connections of optical waveguides, having the following process steps : a) loose insertion of a capillary (2) in a connector cylinder (1), b) acceptance of the capillary (2) between two centering points (19, 20), c) coaxial alignment of an accepting opening (6) of the capillary (2) with the aid of the centering points (19, 20) in relation to the outer periphery of the connector cylinder (1) and d) subsequent fixing of the capillary (2) by hardening of a hardenable adhesive (3) inserted in an annular gap (5).
Compound 527225: 1,4a-dimethyl-7-propan-2-yl-2,3,4,5-tetrahydro-1H-naphthalene

Chemical compound data from PubChem database. IUPAC Name: 1,4a-dimethyl-7-propan-2-yl-2,3,4,5-tetrahydro-1H-naphthalene. Molecular Formula: C15H24. Molecular Weight: 204.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528659: 1,2,3-Propanetricarboxylic acid, 1-[(trimethylsilyl)oxy]-, tris(trimethylsilyl) ester

Chemical compound data from PubChem database. IUPAC Name: tris(trimethylsilyl) 1-trimethylsilyloxypropane-1,2,3-tricarboxylate. Molecular Formula: C18H40O7Si4. Molecular Weight: 480.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Effect of mivacurium 200 and 250 μg/kg in infants during isoflurane anesthesia: a randomized controlled trial [ISRCTN07742712]

Background
          Infants usually respond differently to a neuromuscular relaxant compared to children or adults. Isoflurane is commonly used as an anesthetic gas in infants. In an RCT design, we investigated whether a dose of mivacurium 250 μg/kg results in faster onset of action than 200 μg/kg in infants under isoflurane anesthesia. Spontaneous recovery times and cardiovascular response were also evaluated.
        
        
          Methods
          Twenty-four low surgical risk children, aged 6–24 months, undergoing an elective surgery and requiring tracheal intubation were selected. After anesthetic induction, patients randomly received an iv bolus dose of mivacurium 200 or 250 μg/kg. After maximal relaxation, the patient was intubated. Isoflurane was administered to maintain anesthetic level during the surgical procedure. Neuromuscular function was monitored by accelerometry (TOF-Guard) at the adductor pollicies. The first twitch (T) of the TOF and the T4/T1 were measured. The time-course of heart rate and systolic and diastolic blood pressure were analysed by transforming them into their respective areas under the curve.
        
        
          Results
          Mivacurium 250 μg/kg produced a maximal T block faster than 200 μg/kg, i.e. 2.4 ± 1.1 vs. 3.5 ± 1.4 min (p < 0.05). Spontaneous recovery times were similar in both groups. Heart rate was similar between doses while systolic and diastolic blood pressures were lower with the higher dose (p < 0.05). Flushing was observed in two cases, one in each group.
        
        
          Conclusions
          The maximal effect of mivacurium 250 μg/kg, in infants under isoflurane anesthesia, was present one minute faster than 200 μg/kg. However, it produced a significant cardiovascular response.
National Mental Health Services Survey (N-MHSS): 2017, Data On Mental Health Treatment Facilities

This report presents findings from the 2017 National Mental Health Services Survey (N-MHSS) conducted from March 2017 through December 2017. The N-MHSS collects information from all known facilities in the United States, both public and private, that provide mental health treatment services to people with mental illness.3 The Center for Behavioral Health Statistics and Quality (CBHSQ) of the Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services, plans and directs the N-MHSS.The N-MHSS provides a mechanism for quantifying the dynamic character and composition
Compound 528392: 2,3-Dichloro-6-hydroxybenzaldehyde

Chemical compound data from PubChem database. IUPAC Name: 2,3-dichloro-6-hydroxybenzaldehyde. Molecular Formula: C7H4Cl2O2. Molecular Weight: 191.01. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525846: N,N-Dimethyl-N'-propyl-isobutyramidine

Chemical compound data from PubChem database. IUPAC Name: N,N,2-trimethyl-N'-propylpropanimidamide. Molecular Formula: C9H20N2. Molecular Weight: 156.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Activation of the kinin system in the ovary during ovulation: Role of endogenous progesterone

Background
          Previous work by our group and others has implicated a role for kinins in the ovulatory process. The purpose of the present study was to elucidate whether endogenous progesterone, which is an intraovarian regulator of ovulation, might be responsible for induction of the kinin system in the ovary during ovulation. The gonadotropin-primed immature rat was used as the experimental model, and the role of endogenous progesterone was explored using the antiprogestin, RU486.
        
        
          Results
          The results of the study revealed that RU486 treatment, as expected, significantly attenuated ovulation. Activity of the kinin-generating enzyme, kallikrein, was elevated in the ovary in control animals prior to ovulation with peak values observed at 4 h post hCG, only to fall to low levels at 10 h, with a recovery at 20 h post hCG. RU486 treatment had no significant effect on ovarian kallikrein activity as compared to the control group. Total ovarian kininogen levels in control animals increased significantly at 12–14 h after hCG – coinciding with initiation of ovulation. Thereafter, ovarian kininogen levels fell to low levels at 20 h, only to show a rebound from 24–38 h post-hCG. RU486 treatment had no significant effect on the rise of total ovarian kininogen levels from 12–14 h after hCG; however, from 30–40 h post hCG, RU486-treated animals had significantly higher total ovarian kininogen levels versus control animals, suggesting that endogenous progesterone may act to restrain elevations of kininogens in the post-ovulatory ovary. This robust elevation of ovarian kininogen levels by RU486 was found to be primarily due to an increase in T-kininogen, which is a potent cysteine protease inhibitor.
        
        
          Conclusions
          Taken as a whole, these results suggest that endogenous progesterone does not regulate kallikrein activity or kininogens prior to ovulation, but may provide a restraining effect on T-kininogen levels in the post-ovulatory ovary.
Patent AT-E401115-T1: [Translated] FILTER SNAPPER

A device for applying an axial compressive force to a fluid contamination detection system comprising a cup joined by a frangible connection to a filter ring, the force being sufficient to break the frangible connection and collapse a portion of the ring into the cup without damaging the ring. The device includes a stop element and a platform and an actuating mechanism for reciprocally moving the platform relative to the stop element. In a first position, the distance between the platform and the stop element is greater than the axial length of the detection system when the cup and the filter ring of the funnel are connected to each other, and in a second position, the distance between the platform and the stop element is less than the axial length of the detection system when the cup and the filter ring of the funnel are connected to each other.
Patent AT-E400113-T1: [Translated] DISTRIBUTED DYNAMIC CHANNEL SELECTION IN A COMMUNICATIONS NETWORK

In one embodiment, a first node among a number of distributed nodes capable of forming or reforming a communication network between the nodes, each of the nodes including functionally similar components for forming or reforming such a network, includes a memory for storing values for variables for the node. The first node also includes one or more components collectively operable to: (1) spontaneously and independent of a centralized controller associated with the network, transmit a probe message to one or more of the other nodes for purposes of forming or reforming a network; (2) receive a probe message from a second node, the probe message including values for the variables for the second node; (3) compare the values for the variables for the first node to the values for the variables for the second node within the probe message to determine, independent of a centralized controller associated with the network, whether the first node should set itself to a new channel; and (4) if so, set the first node to the new channel.
Compound 525356: 2,2-Dimethyl-5,6-dithiaheptane

Chemical compound data from PubChem database. IUPAC Name: 3,3-dimethyl-1-(methyldisulfanyl)butane. Molecular Formula: C7H16S2. Molecular Weight: 164.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400244-T1: [Translated] HAIR STOCKING AGENTS CONTAINING SPECIAL POLYALKYLENE GLYCOL HAIR SHAPING AGENTS

Disclosed are hair styling compositions which comprise from about 5% to about 90% by weight of a polyalkylene glycol styling agent that is substantially free of polyalkylene glyceryl ethers, and that has a number average molecular weight of from about 190 to about 1500 and from about 5 to about 35 repeating alkylene oxide radicals wherein each of the repeating alkylene oxide radicals has from 2 to 6 carbon atoms; from about 1% to about 90% by weight of a liquid carrier which can comprise water, an organic solvent, or combinations thereof; and, optionally, from about 5% to about 40% by weight of a propellant. Also disclosed are hair styling compositions which comprise from about 5% to about 90% by weight of a polyalkylene glycol styling agent that has a number average molecular weight of from about 190 to about 1500 and from about 5 to about 35 repeating alkylene oxide radicals wherein each of the repeating alkylene oxide radicals has from 2 to 6 carbon atoms; from about 1% to about 90% by weight of a liquid carrier which can comprise water, an organic solvent, or combinations thereof; and from about 1.5% to about 60% by weight of certain silicones or silicone derivatives and, optionally, propellant.
Public Health Statistics - Gonorrhea cases for females aged 15-44 in Chicago, by year, 2000-2014 - Historical

Note: This dataset is historical only and STI surveillance data do not change once finalized. For the most recent STI data, please refer to the CDPH Health Atlas (chicagohealthatlas.org), the annual HIV/STI surveillance report, and the Getting to Zero Illinois HIV Dashboard (gtzillinois.hiv).

The annual number of newly reported, laboratory-confirmed cases of gonorrhea (Neisseria gonorrhoeae) among females aged 15-44 years and annual gonorrhea incidence rate (cases per 100,000 females aged 15-44 years) with corresponding 95% confidence intervals by Chicago community area, for years 2000 – 2014.  See the full description by clicking on the maroon "About" button on the right-hand side of the screen, and click on the PDF under "Attachments".
Service Locator - Family Planning Title X

<p>This locator tool will help you find Title X family planning centers that provide high quality and cost-effective family planning and related preventive health services for low-income women and men.</p>
<p>Family planning centers offer a broad range of FDA-approved contraceptive methods and related counseling; as well as breast and cervical cancer screening; pregnancy testing and counseling; screening and treatment for sexually transmitted infections (STIs); HIV testing; and other patient education and referrals.</p>
<p>4,400 family planning centers serve about 5 million clients each year. Services are provided through state, county, and local health departments; community health centers; Planned Parenthood centers; and hospital-based, school-based, faith-based, other private nonprofits.</p>
<p>Title X staff are specially trained to meet the contraceptive needs of individuals with limited English proficiency, teenagers, and those confronting complex medical and personal issues such as substance abuse, disability, homelessness or interpersonal and domestic violence.</p>
Compound 526775: 10-Hydroxy-arachidic, methyl ester, tBDMS ether

Chemical compound data from PubChem database. IUPAC Name: methyl 10-[tert-butyl(dimethyl)silyl]oxyicosanoate. Molecular Formula: C27H56O3Si. Molecular Weight: 456.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Behavioral Risk Factor Surveillance Survey: 2017

The Behavioral Risk Factor Surveillance System (BRFSS) is an annual statewide telephone surveillance system designed by the Centers for Disease Control and Prevention (CDC). BRFSS monitors modifiable risk behaviors and other factors contributing to the leading causes of morbidity and mortality in the population. New York State's BRFSS sample represents the non-institutionalized adult household population, aged 18 years and older. Although the overall number of respondents in the BRFSS is more than sufficiently large for statistical inference purposes, subgroup analyses can lead to estimates that are unreliable. Interpreting and reporting weighted numbers that are based on a small, unweighted number of respondents can mislead the reader into believing that a given finding is much more precise than it actually is. The BRFSS follows a rule of not reporting or interpreting percentages based upon a denominator of fewer than 50 respondents (unweighted sample). Both a csv and sas data files are available. For more information, check out http://www.health.ny.gov/statistics/brfss/.
Patent AT-E400116-T1: [Translated] METHOD FOR THE INTEGRATED MANAGEMENT OF A SWITCHING SYSTEM IN A LOCAL NETWORK

The present invention discloses an integrated managing method for switching devices of Local Area Network, in which the switching device broadcasts applying register message including address identification of present switching device on the port connected to a managing device, the managing device turns to the operation of register after receiving the message, and sends back the register response message, the switching device sends handshake message to the managing device in timing after receiving a successful register response message, the managing device sends back the communicating response message, thus the operation of communicating between the managing device and the switching device is accomplished, if the switching device does not receive the communicating response message from the managing device within designated time, it indicates that communication is interrupted and the operation of register starts again; during the process of communicating, the managing device manages the switching device, the switching device sends back the response message to the managing device according to the operation result; IP addresses do not need to be assigned for the switching device in said scheme, thus integrated management and maintenance for network switching device are accomplished, and IP address resource of network is saved. <IMAGE>
NNDSS - TABLE 1PP. Yellow fever to Zika virus disease, non-congenital

NNDSS - TABLE 1PP. Yellow fever to Zika virus disease, non-congenital – 2020.  In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2019 and 2020 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).